Delenex Therapeutics Complements its Management
(Thomson Reuters ONE) -
Delenex Therapeutics AG /
Delenex Therapeutics Complements its Management
Processed and transmitted by Thomson Reuters.
The issuer is solely responsible for the content of this announcement.
Delenex appoints Eric de La Fortelle as CEO and Jakob Schlapbach as CFO
Schlieren, Switzerland, February 1, 2011. Today, Delenex Therapeutics
(« Delenex ») announced the appointments of Eric de La Fortelle as new CEO, and
Jakob Schlapbach as new CFO.
Eric de La Fortelle brings significant experience from the pharmaceutical
industry to Delenex. He served previously in two senior roles at F. Hoffmann-La
Roche ("Roche"). Beginning in 2005, Eric was Global Head, External Research and
Technologies, leading a ten-person group responsible for establishing and
managing around fifty strategic alliances each year in early-stage products and
technologies. In 2008 and 2009, he also served as Global Head, Emerging
Technologies.
Eric de La Fortelle's scientific work contributed to the field of protein
structure determination. The SHARP software, of which he was the initial lead
author, contributed to the resolution of more than a thousand protein structures
by X-ray crystallography.
Eric de La Fortelle is a graduate from Ecole Centrale de Paris, holds a Ph.D. in
structural biology from Paris XI University and an MBA from INSEAD.
Jakob Schlapbach joined Delenex in December, 2010, as CFO. Mr. Schlapbach brings
more than thirty years of banking and industrial financing experience to the
company. He has been CFO of Cytos Biotechnology for more than ten years until
mid-2010 and hold the same position with Ascom group between 1994 and 2000. At
Cytos Biotechnology he has been instrumental in raising funds in the amount of
CHF 262 million from institutional and private investors and played a key role
in the going public of Cytos Biotechnology. He was elected "CFO of the Year" in
2002 by the renowned Swiss newspaper Finanz und Wirtschaft.
Jakob Schlapbach holds an MBA from INSEAD and an economics degree from
University of Berne (lic.rer.pol.).
Thomas Hecht, chairman of Delenex said: "We are pleased and proud to have
attracted two managers of such a high calibre to Delenex. I am convinced that
Eric with his international experience and strong business development &
licensing background has the skillset to lead Delenex to become a significant
player in the field of antibody fragments. I am also looking forward to working
again with Jakob, a seasoned CFO with a long career in finance and in the
biotech area, having broad experience in financial transactions ."
Eric de la Fortelle mentioned: "I am looking forward joining Delenex at this
stage ,where it will move its lead project towards the clinic while building a
strong pipeline from its proven platform technology".
"I am excited about the opportunity to work for Delenex and to support the team
in all financial matters" , Jakob Schlapbach added.
About Delenex Therapeutics AG
Delenex Therapeutics AG is a Swiss biotech company developing therapeutic
antibody fragments targeting serious medical diseases with high unmet need.
These antibody fragments called PENTRA fragments are being designed for
local/topical application by using the benefits of an antibody therapy with only
limited systemic exposure. The PENTRA technology is clinically validated and
delivers antibody therapeutics exhibiting the highest affinity, solubility and
stability all combined with a very low risk of immunogenicity.
Delenex is a spin off from ESBATech AG before its acquisition by Alcon, Inc. in
September 2009 and operates out of laboratories and offices in Zürich-Schlieren.
For further details please contact:
Eric de la Fortelle, CEO
Delenex Therapeutics AG
Wagistrasse 23
CH-8952 Schlieren
Tel: +41 44 730 5180 or e-mail to:info(at)delenex.com
--- End of Message ---
Delenex Therapeutics AG
Wagistrasse 23 Zürich-Schlieren Switzerland
Press Release (PDF):
http://hugin.info/144623/R/1484224/419422.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Delenex Therapeutics AG via Thomson Reuters ONE
[HUG#1484224]
Unternehmensinformation / Kurzprofil:
Datum: 01.02.2011 - 12:27 Uhr
Sprache: Deutsch
News-ID 50934
Anzahl Zeichen: 5135
contact information:
Town:
Zürich-Schlieren
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 173 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Delenex Therapeutics Complements its Management"
steht unter der journalistisch-redaktionellen Verantwortung von
Delenex Therapeutics AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
